Update
$Delcath Systems (DCTH.US)$ Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT1 MINUTE AGO, 9:00 AM EDTVIA PR NEWSWIRESignificantly Higher Overall Response Rate vs Meta-analysis of Historical Controls (36.3% vs. 5.5%)Other Efficacy Endpoints Include a 73.6% Disease Control Rate with a 7.7% Complete Response Rate
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more1